23-Jun-2026
PRNewswire (Mon, 1-Jun 7:30 AM ET)
PRNewswire (Wed, 27-May 7:30 AM ET)
Market Chameleon (Tue, 26-May 5:24 AM ET)
PRNewswire (Tue, 26-May 7:30 AM ET)
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
PRNewswire (Mon, 4-May 4:02 PM ET)
Biohaven Prices $175 Million Public Offering—What Could This Mean for Future Growth?
Market Chameleon (Wed, 12-Nov 2:32 AM ET)
Market Chameleon (Mon, 10-Nov 3:47 AM ET)
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Biohaven Ltd. Common Shares trades on the NYSE stock market under the symbol BHVN.
As of June 23, 2026, BHVN stock price declined to $14.78 with 2,253,790 million shares trading.
BHVN has a beta of 2.09, meaning it tends to be more sensitive to market movements. BHVN has a correlation of 0.07 to the broad based SPY ETF.
BHVN has a market cap of $2.22 billion. This is considered a Mid Cap stock.
Last quarter Biohaven Ltd. Common Shares reported $0 in Revenue and -$.69 earnings per share. This fell short of revenue expectation by $-8 million and exceeded earnings estimates by $.09.
In the last 3 years, BHVN traded as high as $62.21 and as low as $7.48.
The top ETF exchange traded funds that BHVN belongs to (by Net Assets): XBI, IWM, PINK, VXF, IWO.
BHVN has underperformed the market in the last year with a return of +2.2%, while SPY returned +24.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BHVN shares. However, BHVN has outperformed the market in the last 3 month and 2 week periods, returning +65.5% and +32.9%, while SPY returned +13.4% and -0.5%, respectively. This indicates BHVN has been having a stronger performance recently.
BHVN support price is $14.46 and resistance is $16.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHVN shares will trade within this expected range on the day.
